Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.
MINIMAL Requirements: Google Chrome 24+, Mozilla Firefox 20+, Internet Explorer 11, Opera 15–18, Apple Safari 7, SeaMonkey 2.15-2.23
Make sure you check these pages frequently, or sign up to our newsletter! To sign up for ESMO newsletters, create a myESMO account here and select the newsletters you’d like to receive.
Osimertinib provides longer overall survival than a comparator EGFR tyrosine kinase inhibitor in EGFR mutation–positive, advanced non-small cell lung cancer
Evidence for efficacy is based on the results from the ELEVATE-TN and ASCEND studies
New indication concerns combination therapy with rituximab for previously treated follicular lymphoma
IMbrave150 results may be practice changing in the first-line setting for unresectable hepatocelluar carcinoma
Characteristics of cancer in adolescents and young adults are defined and suggestions provided to improve survival
Molecular classification provides deeper insights into biology of colorectal cancer, but at present time with no impact on clinical decision-making
Important advance in the management of patients who represent an otherwise unmet medical need
Evidence for efficacy is based on the results from BGB-3111-206 and BGB-3111-AU-003 studies
New indication concerns adjuvant treatment of adult patients with HER2-positive early breast cancer who have residual invasive disease
The results of the GOG-0213 study
The results of KEYNOTE-158 study
Researchers uncover how immune checkpoint inhibitor response relies on the evolved efficiency of HLA-mediated immunity
This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.
For more detailed information on the cookies we use, please check our Privacy Policy.
Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.
